Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

A Phase IV, Non-Randomized, Open-Label Trial Evaluating The Safety Of 625 mg Formulation Of VIRACEPT When Administered To HIV-Infected Women During Pregnancy

This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum. The study will also evaluate the pharmacokinetics of VIRACEPT

Inclusion Criteria:

• HIV infection
• Second trimester of pregnancy

Exclusion Criteria:

• Major current or prior history of obstetrical complications
• Serious current medical diseases
• Evidence of HIV virus resistance to antiretroviral agents